Vaccine composition with aluminium hydroxide nanoparticles
A vaccine composition comprising at least one antigen and one adjuvant, characterized in that the adjuvant comprises sterile-filterable nanoparticles comprising pseudo-boehmite and polyacrylate.
1. A vaccine composition comprising at least one antigen and an adjuvant, wherein the adjuvant comprises nanoparticles comprising pseudo-boehmite and polyacrylate, and wherein the size of the nanoparticles is such that they are able to pass through a sterilizing filter of 220 nm size pore.
2. The vaccine composition as claimed in claim 1 , wherein the core of the nanoparticle consists essentially of pseudo-boehmite and the polyacrylate is located essentially at the surface of the nanoparticles.
3. The vaccine composition as claimed in claim 1 , wherein the pseudo-boehmite is at least 90% of the mass of the nanoparticles.
4. The vaccine composition as claimed claim 1 , wherein the size of the nanoparticles is less than 300 nm.
5. The vaccine composition as claimed in claim 1 , wherein the composition comprises at least one influenza antigen.
6. The vaccine composition as claimed in claim 1 , wherein the composition comprises at least one tetanus protein.
7. A method of making a vaccine composition comprising combining nanoparticles comprising pseudo-boehmite and polyacrylate with at least one antigen, wherein the size of the nanoparticles is such that they are able to pass through a sterilizing filter of 220 nm size pore.
8. The method of claim 7 , wherein the vaccine composition is formulated for intradermal administration.
9. The method of claim 8 , wherein the vaccine composition comprises at least one influenza antigen.
10. A process for preparing a vaccine composition as claimed in claim 1 , the process comprising,
preparing nanoparticles comprising pseudo-boehmite and polyacrylate, wherein the size of the nanoparticles is such that they are able to pass through a sterilizing filter of 220 nm size pore,
filtering said nanoparticles by means of a sterilizing filter,
adding at least one vaccine antigen to said nanoparticles,
and, optionally, performing an additional filtration.
11. The vaccine composition as claimed in claim 2 , wherein the size of the nanoparticles is less than 220 nm.
12. The vaccine composition as claimed in claim 11 , wherein the pseudo-boehmite is at least 90% of the mass of the nanoparticles.
13. The vaccine composition as claimed in claim 12 , wherein the composition comprises at least one influenza antigen.
14. The vaccine composition as claimed in claim 13 , wherein the composition comprises at least one tetanus protein.
15. The method of claim 7 , wherein the size of the nanoparticles is less than 220 nm.
16. The method as claimed in claim 15 , wherein the pseudo-boehmite is at least 90% of the mass of the nanoparticles.
17. The method as claimed in claim 16 , wherein the composition comprises at least one influenza antigen.
18. The method as claimed in claim 16 , wherein the composition comprises at least one tetanus antigen.